$7.63
+0.76
(+11.06%)▲
10.22%
Downside
Day's Volatility :12.52%
Upside
2.55%
44.82%
Downside
52 Weeks Volatility :61.62%
Upside
30.45%
Period | Kala Bio Inc | |
---|---|---|
3 Months | 30.43% | |
6 Months | 13.66% | |
1 Year | 29.98% | |
3 Years | -92.9% |
Market Capitalization | 37.7M |
Book Value | $2.98 |
Earnings Per Share (EPS) | -13.52 |
PEG Ratio | 0.0 |
Wall Street Target Price | 15.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.25% |
Return On Equity TTM | -248.11% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.3M |
EBITDA | -41.0M |
Diluted Eps TTM | -13.52 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -11.75 |
EPS Estimate Next Year | -6.67 |
EPS Estimate Current Quarter | -4.4 |
EPS Estimate Next Quarter | -4.53 |
What analysts predicted
Upside of 96.59%
Sell
Neutral
Buy
Kala Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Kala Bio Inc | 46.03% | 13.66% | 29.98% | -92.9% | -96.14% |
Regeneron Pharmaceuticals, Inc. | -18.16% | -14.42% | 3.52% | 34.42% | 140.62% |
Biontech Se | -5.81% | 20.18% | 11.4% | -51.12% | 460.49% |
Alnylam Pharmaceuticals, Inc. | 2.41% | 83.28% | 68.63% | 50.84% | 200.09% |
Vertex Pharmaceuticals Incorporated | 10.42% | 23.33% | 40.2% | 170.42% | 155.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Kala Bio Inc | 11.21 | NA | 0.0 | -11.75 | -2.48 | -0.4 | NA | 2.98 |
Regeneron Pharmaceuticals, Inc. | 20.41 | 20.41 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.1 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Kala Bio Inc | Buy | $37.7M | -96.14% | 11.21 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 140.62% | 20.41 | 33.61% |
Biontech Se | Buy | $25.9B | 460.49% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.1B | 200.09% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 155.94% | 32.84 | -4.51% |
Baker Bros Advisors LP
SR ONE CAPITAL MANAGEMENT, LP
ADAR1 Capital Management LLC
UBS O'Connor LLC
Millennium Management LLC
Vanguard Group Inc
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Organization | Kala Bio Inc |
Employees | 43 |
CEO | Mr. Mark T. Iwicki |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$7.63
+11.06%
Rigel Resource Acquisition Corp
$7.63
+11.06%
Fortune Rise Acquisition Corp
$7.63
+11.06%
Canada Goose Holdings Inc.
$7.63
+11.06%
J W Mays Inc
$7.63
+11.06%
American Shared Hospital Services
$7.63
+11.06%
Cambria Shareholder Yield Etf
$7.63
+11.06%
J-long Group Ltd.
$7.63
+11.06%
Cps Technologies Corp
$7.63
+11.06%